Hologic, Inc. revised earnings guidance for the Fiscal year 2023. For the year, the Company expects revenues of $3,850 million to $4,000 million compared to previous guidance of $3,700 million to $3,900 million and GAAP EPS of $2.69 to $2.99 compared to previous guidance of $2.51 to $2.81.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
75.92 USD | +1.03% | +0.14% | +6.42% |
May. 09 | Argus Adjusts Price Target on Hologic to $95 From $89 | MT |
May. 06 | Lumos Diagnostics Concludes Initial Phase of Development Deal with Hologic for Fetal Fibronectin Test; Shares Jump 6% | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.42% | 17.54B | |
+11.41% | 226B | |
+9.63% | 188B | |
+13.26% | 137B | |
+25.96% | 108B | |
+0.11% | 63.19B | |
+12.49% | 52.26B | |
+5.62% | 51B | |
+7.16% | 43.89B | |
+5.79% | 38.07B |
- Stock Market
- Equities
- HOLX Stock
- News Hologic, Inc.
- Hologic, Inc. Revises Earnings Guidance for the Fiscal Year 2023